Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.
Awareness
Hepatitis C virus
Kuwait
Micro-elimination
Prescribers
Registries
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Aug 2020
14 Aug 2020
Historique:
received:
30
03
2020
revised:
04
06
2020
accepted:
22
07
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
The hepatitis C virus (HCV) is estimated to affect 71 million people worldwide. In 2016, the World Health Organization adopted the first global health sector strategy to eliminate viral hepatitis as a public health threat by 2030. In December 2018, the European Association for the Study of the Liver, International Liver Foundation convened an expert panel to address the elimination of HCV in Kuwait. Several steps have already been taken to eliminate HCV in Kuwait, including free HCV treatment for Kuwait's citizens, high blood safety standards, and the implementation of screening and awareness programs. The expert panel made several recommendations aimed at accelerating the elimination of HCV in Kuwait: The development of a national strategy and action plan to guide all HCV elimination activities; the formation of a coordination mechanism to support collaboration between hepatitis working committees; the prioritization of micro-elimination at primary, secondary or tertiary facilities, in prisons and rehabilitation centers; and ensuring the involvement of multiple stakeholders - including relevant civil society groups - in all activities. Enhanced screening and linkage to care should be prioritized in Kuwait, with the expansion of the prescriber base to primary healthcare providers and nurse practitioners to be considered. Raising awareness and educating people about HCV infection also remain essential to achieve the goal of HCV elimination. Lastly, a national HCV registry should be developed to help monitor the implementation of viral hepatitis plans and progress towards achieving national and international targets.
Identifiants
pubmed: 32874054
doi: 10.3748/wjg.v26.i30.4415
pmc: PMC7438195
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4415-4427Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare no conflicts of interest related to the study. Writing support was provided by Turacoz Healthcare Solutions which was funded by Gilead Sciences.
Références
Clin Infect Dis. 2016 Feb 1;62(3):298-304
pubmed: 26628566
East Mediterr Health J. 2019 Jul 24;25(5):362-365
pubmed: 31364761
J Viral Hepat. 2018 Mar;25 Suppl 1:6-17
pubmed: 29508946
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):189-193
pubmed: 30321071
Hepatology. 2015 Jan;61(1):402
pubmed: 24797497
J Viral Hepat. 2016 May;23(5):366-74
pubmed: 26840570
Hepat Med. 2018 Sep 28;10:117-132
pubmed: 30319294
Value Health Reg Issues. 2019 May;18:112-120
pubmed: 30921591
Harm Reduct J. 2018 Dec 11;15(1):62
pubmed: 30538000
Open Forum Infect Dis. 2017 May 27;4(3):ofx109
pubmed: 28752101
Curr Treat Options Infect Dis. 2018;10(4):431-446
pubmed: 30524209
Can Commun Dis Rep. 2018 Jul 05;44(7-8):157-165
pubmed: 31011296
Lancet. 2019 Mar 30;393(10178):1319-1329
pubmed: 30704789
Drug Alcohol Rev. 2019 Mar;38(3):264-269
pubmed: 30548702
F1000Res. 2019 Jan 14;8:
pubmed: 30687501
J Virus Erad. 2019 Jan 1;5(1):60-66
pubmed: 30800429
J Intern Med. 2019 Nov;286(5):503-525
pubmed: 31472002
Am Fam Physician. 2015 Jun 15;91(12):835-42
pubmed: 26131943
Am J Public Health. 2015 Feb;105(2):302-3
pubmed: 25521877
Int J Health Plann Manage. 2019 Apr;34(2):e1247-e1256
pubmed: 30901129
Int J Infect Dis. 2016 May;46:116-25
pubmed: 26996460
Int J Environ Res Public Health. 2019 Jun 02;16(11):
pubmed: 31159479
J Int AIDS Soc. 2019 Jul;22(7):e25360
pubmed: 31347280
MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):773-776
pubmed: 28749925
Z Gastroenterol. 2019 May;57(5):584-592
pubmed: 31083746
J Hepatol. 2017 Oct;67(4):665-666
pubmed: 28760329
Trends Microbiol. 2004 Feb;12(2):96-102
pubmed: 15036326
Int J Infect Dis. 2019 Aug;85:141-142
pubmed: 31229938
J Clin Transl Hepatol. 2019 Sep 28;7(3):226-231
pubmed: 31608214
J Hepatol. 2018 May;68(5):932-939
pubmed: 29274408
World J Gastroenterol. 2017 Jan 7;23(1):151-166
pubmed: 28104991
Ann Intern Med. 2017 Sep 5;167(5):311-318
pubmed: 28785771
J Viral Hepat. 2016 Apr;23(4):274-81
pubmed: 26572798
Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059
pubmed: 30874328
Open Forum Infect Dis. 2019 Jul 1;6(7):
pubmed: 31363775
Hepatology. 2015 Jan;61(1):402-3
pubmed: 24797358
J Hepatol. 2019 Jun;70(6):1043-1045
pubmed: 30948269
Ann Gastroenterol. 2019 Jul-Aug;32(4):321-329
pubmed: 31263353
Bull World Health Organ. 1998;76 Suppl 2:22-5
pubmed: 10063669
Am J Manag Care. 2018 May;24(5):232-238
pubmed: 29851440
J Am Med Inform Assoc. 2009 Nov-Dec;16(6):775-83
pubmed: 19717794
PLoS Med. 2015 Mar 10;12(3):e1001795
pubmed: 25757228
Hepatol Med Policy. 2018 Sep 29;3:12
pubmed: 30288334
Open Forum Infect Dis. 2019 Aug 14;:
pubmed: 31412130
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Semin Liver Dis. 2018 Aug;38(3):181-192
pubmed: 29986353
Clin Infect Dis. 2019 Nov 27;69(12):2218-2227
pubmed: 31352481
BMJ Open. 2019 May 9;9(5):e026464
pubmed: 31072855
Harm Reduct J. 2019 Jul 5;16(1):42
pubmed: 31277665
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Lancet HIV. 2018 Nov;5(11):e605
pubmed: 30507440